Psyence Biomedical Ltd. (PBM) Cash & Equivalents (2023 - 2026)

Psyence Biomedical's Cash & Equivalents history runs 4 years deep, the most recent figure standing at $7.4 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 21.35% year-over-year to $7.4 million; the TTM figure through Mar 2026 stood at $7.4 million (up 21.35% YoY), while the FY2026 annual figure was $7.4 million, up 21.35% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $7.4 million, up from $7.1 million in the prior quarter.
• The five-year high for Cash & Equivalents was $7.4 million in Q1 2026, with the low at $605480.0 in Q3 2023.
• The 4-year median for Cash & Equivalents is $1.9 million (2024), against an average of $3.6 million.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents plunged 45.05% in 2024, then jumped 736.78% in 2025.
• Psyence Biomedical's Cash & Equivalents stood at $605480.0 in 2023, then soared by 219.17% to $1.9 million in 2024, then jumped by 269.98% to $7.1 million in 2025, then gained by 4.12% to $7.4 million in 2026.
• Business Quant data shows PBM's Cash & Equivalents at $7.4 million in Q1 2026, $7.1 million in Q3 2025, and $6.1 million in Q1 2025.